CVS Caremark Announces Name Change to CVS Health to Reflect Broader Health Care Commitment ...
CVS Caremark Corporation (NYSE: CVS) announced today that it is changing its corporate name to CVS Health to reflect its broader health care commitment and i...
By: Justmeans
Read the original here:
Delaney #39;s Story
TENNANT RELEASES POWERFUL NEW AD SHARING STORY OF DAUGHTER #39;S OPEN HEART SURGERY U.S. Senate Nominee: #39;I will never go back to the days of letting insurance companies deny coverage to our...
By: Natalie Tennant for Senate
See original here:
Seen At 11: Families Fight Home Health Care Dangers
One Staten island family said that the aides they relied on to help their father actually put his life at risk. CBS 2 #39;s Kristine Johnson has more. Official Site: http://newyork.cbslocal.com/...
By: CBS New York
View original post here:
Health care diplomacy trumps political tension between the United States and Russia for a delegation of doctors and nurses visiting La Crosse to glean ideas to improve care back home.
The two doctors and three nurses are rubbing elbows with their counterparts and others at Gundersen Health System this week as part of World Services of La Crosses Bridging Cancer Care project.
Our main goal is to improve the health of our patients, their quality of life, Dr. Mikhail Frolov said through an interpreter in answer to a question about strained U.S.-Russian relations. The politics between our countries doesnt make a difference.
On the other hand, their concerns mirror those of their U.S. colleagues not only in health care but also in costs.
Nurse Margarita Vakulina said delegation members learned valuable lessons from the start Monday, as they observed the role of Gundersens nurse coordinators in streamlining care. The position, which does not exist in Russian health care, involves working with patients and dovetailing care with providers and hospital services.
We saw how much money can be saved with just a small number of nurses coordinating care, Vakulina said. If you are talking about costs, this is very important. We are always looking for better practices.
Russias health care system has major differences, Frolov said, adding, Health care in Russia is a government system, with a different structure, different financing and different insurance.
Nurse Irina Azrapkina said, What we can see now is that we cant say one is better than the other all are good, but in different ways.
But we already know that small steps in practice can create big changes in care, Frolov said.
One such change involves patient education, particularly regarding cancer the second-leading cause of death in Russia, delegation members said.
See original here:
Russian doctors, nurses practice health-care diplomacy in La Crosse
Compared with women, American men have worse access to reproductive and sexual health care, research shows, a disparity fueled in part by the lack of standard clinical guidelines on the types and timing of exams, tests and treatments that should be offered to all men of reproductive age.
Now a report, developed jointly by Johns Hopkins experts and the federally funded Male Training Center for Family Planning and Reproductive Health, aims to fill that need.
The report, released on Sept. 9, is designed for primary care clinicians, male health specialists and health officials, and outlines steps to fix the problem. Among other recommendations the document enumerates the reproductive and sexual health screening tests, exams and interventions that all men should receive regularly. The report also offers guidance to clinicians on how to discuss reproductive and sexual health issues, including how to prevent unplanned pregnancies and sexually transmitted infections.
"Many clinicians forgo delivering these critical services because of a lack of uniform guidelines, confusion about the benefits of certain tests, or merely because men's sexual or reproductive health is not on a physician's radar," says report lead author Arik Marcell, M.D., M.P.H., an adolescent medicine expert at the Johns Hopkins Children's Center. "We hope this document will lay the foundation for improving access to care and help us close, or at least narrow, the gender gap in reproductive health."
The experts note that improving men's sexual health will also help sustain recent gains in women's reproductive health.
"Over the last decade, women's access to reproductive and sexual health services has improved by leaps and bounds. This is a laudable achievement, but only half the battle," says report co-author Anne Rompalo, M.D., Sc.M., an infectious disease specialist and epidemiologist at Johns Hopkins Bayview Medical Center. "Our next step should be ensuring that American men have equal access to such critical services because population-wide benefits can only be sustained if both men and women receive equal attention to sexually transmitted diseases and reproductive health problems."
Specifically, the report recommends that clinicians provide the following services to reproductive-age males, including teens, at least annually: A comprehensive clinical history and exam that include screening for mental disorders, depression, and alcohol and drug use Discussion of a patient's desire to have a family and development of an individualized plan reflecting any relevant preconception health needs A thorough sexual health assessment, including conversations about sexual practices and partners Screening for HIV and other sexually transmitted infections Discussion of intimate partner violence and any problems related to sexual function, which may signal other underlying disorders such as heart disease A detailed vaccination history A panel of lab tests for certain sexually transmitted infections Counseling on safer sex practices, including condom use, pregnancy prevention and preconception health, and counseling on sexuality, sexual identity, relationships and sexual dysfunction
"Clinicians can utilize these guidelines to transform access to sexual and reproductive health services for male patients," says Melissa Weiler Gerber, president and CEO of AccessMatters, formerly Family Planning Council, the host organization for the Male Training Center run in collaboration with the Johns Hopkins University School of Medicine. "We are confident these groundbreaking recommendations will make the delivery of services to males more comprehensive, regardless of where they receive their healthcare."
The report also urges clinicians to engage a patient's sexual partner in reproductive and sexual health conversations and to provide services to men who have sex with men that go beyond HIV counseling and prevention. Such couples, the authors say, may have other reproductive and family planning needs.
The report highlights areas that merit special attention among male teens and recommends that: Physicians specifically engage teens in talks about their transition into adulthood, sexual identity, sexual orientation and relevant risk factors. Clinicians remain hyper-vigilant about mental health issues among gay, bisexual and transgender teens due to these groups' well-known risk for depression, substance abuse and suicide.
View original post here:
'Must-have' sexual health services for men outlined in report
RICHMOND, Va. (AP) -- Virginia Gov. Terry McAuliffe announced scaled back plans Monday to increase health care coverage for the state's poor, but it will not provide coverage for the vast majority of the 400,000 low-income adults who would have been eligible for an expanded Medicaid program.
The only low-income adults eligible for new health coverage under McAuliffe's plans would be about 20,000 currently uninsured residents who have a severe mental illness.
The governor has made expanding Medicaid using mostly federal funds a top priority and has repeatedly promised that he would do so. But he said Monday that he does not have the authority to do it without the General Assembly, where the Republican majority staunchly opposes expansion.
"Trust me, If I could do this on my own I would do it," McAuliffe said at a Capitol news conference. He added that he's not giving up on expansion and remains optimistic that it can be done in the future.
In place of Medicaid expansion, McAuliffe announced a 10-point plan Monday aimed at encouraging adults and children already eligible for publicly subsidized health care coverage to enroll in various programs.
The state and the federal government would each pay about $80 million a year to cover the costs of new coverage for uninsured residents with a severe mental illness. The plan still has to be approved by the federal Centers for Medicare and Medicaid Services.
The governor also plans to begin including dental coverage for about 45,000 pregnant women who already receive publicly funded health care and to allow state workers to enroll their children FAMIS, an insurance program for low-income children whose families don't qualify for Medicaid.
Read more:
By Steve Angeles, ABS-CBN North America Bureau
Sept. 9, 2014
LOS ANGELES While President Barack Obama has touted the Affordable Care Act as one of his biggest accomplishments in office, community advocates say many are still left out, especially because of their immigration status.
One California lawmaker is trying to change that with the Health Care for All bill.
The current Affordable Care Act aims to give health coverage to millions of uninsured Americans.
This new bill is expected to be re-introduced by State Sen. Ricardo Lara in November, and like the previous bill, it is expected to be co-sponsored by Filipino American Assemblyman Rob Bonta.
Senator Lara spoke at a New America Media briefing recently.
Its going to save us money in the long term, she said. Were going to be able to have a healthier community, and when we say health care for all, we mean health care for all. Unfortunately, the federal government doesnt cover our undocumented communities, and we have a lot of families who are mixed households where some have health insurance and some dont, because of immigration status.
Undocumented immigrants say while they wait for immigration reform to pass or for President Obama to issue executive orders to give them deportation relief, staying healthy has been a challenge.
We all go through aches and pains, and a lot rely on over-the-counter medicines, said Alessandro Negrete, an undocumented immigrant. A lot of us go to emergency rooms and if we were a smart state we would realize that preventive care is a lot less costly than emergency care. A lot of those services provided wed save a lot of money.
Continue reading here:
CA senator looks to provide health care for states undocumented
Contact Information
Available for logged-in reporters only
Newswise New York, NYSeptember 9, 2014Led by Itsik Peer, associate professor of computer science at Columbia Engineering, a team of researchers has created a data resource that will improve genomic research in the Ashkenazi Jewish population and lead to more effective personalized medicine. The team, which includes experts from 11 labs in the New York City area and Israel, focused on the Ashkenazi Jewish population because of its demographic history of genetic isolation and the resulting abundance of population-specific mutations and high prevalence of rare genetic disorders. The Ashkenazi Jewish population has played an important role in human genetics, with notable successes in gene mapping as well as prenatal and cancer screening. The study was published online on Nature Communications today.
Our study is the first full DNA sequence dataset available for Ashkenazi Jewish genomes, says Peer, who is also a co-chair of the Health Analytics Center at Columbias Institute for Data Sciences and Engineering, as well as a member of its Foundations of Data Science Center. With this comprehensive catalog of mutations present in the Ashkenazi Jewish population, we will be able to more effectively map disease genes onto the genome and thus gain a better understanding of common disorders. We see this study serving as a vehicle for personalized medicine and a model for researchers working with other populations.
To help in his hunt for disease genes, Peer founded The Ashkenazi Genome Consortium (TAGC) in September 2011 with Todd Lencz, an investigator at The Feinstein Institute for Medical Research, director of the Laboratory of Analytic Genomics at the Zucker Hillside Hospital, and associate professor of molecular medicine and psychiatry at the Hofstra North Shore-LIJ School of Medicine. The other TAGC members, who are providing expertise in the diseases they are studying, are: Gil Atzmon, associate professor of medicine and genetics, Albert Einstein College of Medicine (genetics of longevity and diabetes); Lorraine Clark, associate professor of clinical pathology and cell biology and co-director, Personalized Genomic Medicine Laboratory, Columbia University Medical Center, Laurie Ozelius, associate professor at Icahn School of Medicine at Mount Sinai, and Susan Bressman, chair of neurology at Mount Sinai Beth Israel (Parkinsons disease and related neurological phenotypes); Harry Ostrer, professor of pathology, genetics, and pediatrics, Albert Einstein College of Medicine (radiogenomics, cancers and rare genetic disorders); Ken Offit, chief of clinical genetics at Memorial Sloan Kettering Cancer Center (breast, ovarian, colon and prostate cancers, lymphoma); Inga Peter, associate professor of genetics and genomic sciences, and Judy Cho, professor of medicine and professor of genetics and genomic sciences, both at The Mount Sinai Hospital(inflammatory bowel disease); and Ariel Darvasi, vice-dean of The Faculty of Life Sciences at The Hebrew University of Jerusalem (multiple diseases).
Before the TAGC study, data was available for a limited number of DNA markers (only approximately one in every 3000 letters of DNA) that are mostly common in Europeans. The TAGC researchers performed high-depth sequencing of 128 complete genomes of Ashkenazi Jewish healthy individuals. They compared their data to European samples, and found that Ashkenazi Jewish genomes had significantly more mutations that had not yet been mapped. Peer and his team analyzed the raw data and created a comprehensive catalog of mutations present in the Ashkenazi Jewish population.
The TAGC database is already proving useful for clinical genomics, identifying specific new mutations for carrier screening. Lencz explains: TAGC advances the goal of bringing personal genomics to the clinic, as it tells the physician whether a mutation in a patients genome is shared by healthy individuals, and can alleviate concerns that it is causing disease. Without our work, a patients genome sequence is much harder to interpret, and more prone to create false alarms. We have eliminated two thirds of these false alarms.
The TAGC study further enables more effective discovery of disease-causing mutations, since some genetic factors are observable in Ashkenazi individuals but essentially absent elsewhere. Moreover, the demography of the Ashkenazi population, the largest isolated population in the U.S., enables large-scale recruitment of study patients and hence more genetic discoveries than in other well-known isolated populations like the Amish and Hutterites locally, or the Icelanders overseas. The researchers expect that medical insights from studies of specific populations will also be relevant to general populations as well.
The TAGC teams findings also shed light on the long-debated origin of Ashkenazi Jews and Europeans. The genetic data indicates that the Ashkenazi Jewish population was founded in the late medieval times by a small number, effectively only hundreds of individuals, whose descendants expanded rapidly while remaining mostly isolated genetically.
Our analysis shows that Ashkenazi Jewish medieval founders were ethnically admixed, with origins in Europe and in the Middle East, roughly in equal parts, says Shai Carmi, a post-doctoral scientist who works with Peer and who conducted the analysis. TAGC data are more comprehensive than what was previously available, and we believe the data settle the dispute regarding European and Middle Eastern ancestry in Ashkenazi Jews. In addition to illuminating medieval Jewish history, our results further pave the way to better understanding European origins, millennia before. For example, our data provides evidence for todays European population being genetically descendant primarily from late mid-eastern migrations that took place after the last ice age, rather than from the first humans to arrive to the continent, more than 40,000 years ago.
Link:
This article was originally published on The Conversation.
The past few decades have seen enormous progress being made in synthetic biology the idea that simple biological parts can be tweaked to do our bidding. One of the main targets has been hacking the biological machinery that nature uses to produce chemicals. The hope is once we understand enough we might be able to design processes that convert cheap feedstock, such as sugar and amino acids, into drugs or fuels. These production lines can then be installed into microbes, effectively turning living cells into factories.
Taking a leap in that direction, researchers from Stanford University have created a version of bakers yeast (Saccharomyces cerevisiae) that contains genetic material of the opium poppy (Papaver somniferum), bringing the morphine microbial factory one step closer to reality. These results published in the journal Nature Chemical Biology represent a significant scientific success, but eliminating the need to grow poppies may still be years away.
If dog has been mans best friend for thousands of years or more, the humble yeast has long been mans second-best friend. The single-cell organism has been exploited by human societies to produce alcoholic beverages or bread for more than 4,000 years.
Like any animal or plant that mankind domesticated, there has been a particular interest in the study and optimisation of yeast. When breeding turned into a scientific discipline, it quickly became a model organism for biological experiments. And in 1996, its complete genome was the first sequenced from a eukaryotic organism the more advanced tree of life. This extensive knowledge of yeast biology makes it an attractive platform for synthetic biology.
In the new study, Christina Smolke and her team further show that yeast could be a good candidate for the production of opioids a class of drugs that includes morphine. To achieve this transformation, Smolke would need a complete biological pathway required to produce complex opioids.
In 2008 she got the first hint on successfully fermenting simple sugars to make salutaridine, an opioid precursor. Then in 2010, a Canadian team identified the last two missing pieces of the morphine puzzle in the genome of opium poppy.
Using these biological parts from plants, together with some from bacteria, Smolke has now created yeast that can produce many natural and unnatural opioids. All it takes is to feed the microbes an intermediary molecule extracted from the poppy plant called thebaine.
These results bring the technology one step closer to microbial factories that can produce pharmaceutical molecules in a tank rather than in the field. What is left now is for Smolke to find a way to turn salutaridine into thebaine efficiently. Filling this gap may allow her to create a yeast strain producing opioids directly from sugars.
See the rest here:
Hoping to encourage sufficient investments by pharmaceutical companies in expensive gene therapies, which often consist of a single treatment, a Penn researcher and the chief medical officer of CVS Health outline an alternative payment model in this month's issue of Nature Biotechnology. They suggest annuity payments over a defined period of time and contingent on evidence that the treatment remains effective. The approach would replace the current practice of single, usually large, at-point-of-service payments.
"Unlike most rare disease treatments that can continue for decades, gene therapy is frequently administered only once, providing many years, even a lifetime, of benefit," says James M. Wilson, MD, PhD, professor of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. "Under current reimbursement policies, private insurers and the government typically pay for this therapy once: when it is administered. But these individual payments could reach several million dollars each under current market conditions. We're proposing a different approach that spreads payments out and only keep coming if the patient continues to do well."
Wilson and co-author Troyen A. Brennan, MD, JD, MPH, chief medical officer of CVS Health, note that while large single payments for gene therapy may be the simplest approach, they carry substantial encumbrances. For example, approval of gene therapy treatments is unavoidably based on data derived from trials carried out over several years at most -- considerably shorter than the expected duration of the therapy. Payers may therefore be unwilling to pay large up-front sums for treatments whose long-term benefit has not been established. Additionally, large payments for medications, such as the $84,000-a-patient cost of the hepatitis C treatment Sovaldi, have been criticized in the prevailing climate of curbing health care costs. This, despite the fact that effective gene therapy may reduce the overall financial burden to the health care system.
Wilson and Brennan further note that while a liver transplant, for example, can cost up to $300,000, physicians and hospitals that "transplant livers know they will be compensated at market rates through existing contracts -- gene developers lack that assurance." Annuity payments, they say, could help address these problems.
An example of an annuity-type disbursement could be a hypothetical payment of $150,000 per year for a certain number of years for gene-therapy-based protein replacement for patients with hemophilia B -- so long as the therapy continues to work. According to the authors, the cumulative amount should be less than the cost of a one-time payment of $4-6 million, which would be the expected rate for a gene-based therapy to be comparatively priced to existing, conventional therapies for hemophilia B. "One would presume," they write, "that gene therapy will have to represent a discount in order for insurers to approve its use."
"The annuity model that we're proposing would eliminate the misguided incentive to invest in drugs and treatments with ongoing revenue streams but which require continuing, perhaps lifetime daily administration, with all the attendant inconveniences and burdens to patients and their families, as well as direct and indirect costs to the nation's health system," says Wilson.
The authors point out that gene therapy differs substantially from the case of "orphan" drugs. Development of the latter, which target rare diseases affecting small patient populations, is supported by the Orphan Drug Act of 1983, which provides pharmaceutical manufacturers with grants, tax credits, and an extended period of market exclusivity for their medications. What's more, in virtually all of these cases, the business costs of developing the drugs are further attenuated by ongoing administration of -- and payment for -- the medication over the lifetime of the patient. "The contrast with gene therapy, especially that which produces a durable cure with one administration," the authors write, "is clear."
Adding further details to their proposal, the authors write that "The original annuity payment could be set with certain types of 're-opener' clauses, such as with patent expiration [death], or if a less expensive new therapy came on line -- thus subjecting the gene therapy annuity to the same vagaries of market competition that standard pharmaceuticals face."
A crucial issue would be the calculation of the annual annuity payment. One option would be for the government to set the price through the Medicare program, since many of the patients with rare diseases are disabled and thus qualify for Medicare. The Medicare rate could in turn become a benchmark for the commercial market.
Another key test in developing an annuity model is determining the correct linkage between payments and the therapy's continued effectiveness and safety. In most diseases, this would entail identifying a biomarker reasonably correlated with efficacy, for example, plasma measures of clotting in hemophilia patients treated with gene therapy.
See more here:
PUBLIC RELEASE DATE:
9-Sep-2014
Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine http://www.twitter.com/PennMedNews
PHILADELPHIA - Hoping to encourage sufficient investments by pharmaceutical companies in expensive gene therapies, which often consist of a single treatment, a Penn researcher and the chief medical officer of CVS Health outline an alternative payment model in this month's issue of Nature Biotechnology. They suggest annuity payments over a defined period of time and contingent on evidence that the treatment remains effective. The approach would replace the current practice of single, usually large, at-point-of-service payments.
"Unlike most rare disease treatments that can continue for decades, gene therapy is frequently administered only once, providing many years, even a lifetime, of benefit," says James M. Wilson, MD, PhD, professor of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. "Under current reimbursement policies, private insurers and the government typically pay for this therapy once: when it is administered. But these individual payments could reach several million dollars each under current market conditions. We're proposing a different approach that spreads payments out and only keep coming if the patient continues to do well."
Wilson and co-author Troyen A. Brennan, MD, JD, MPH, chief medical officer of CVS Health, note that while large single payments for gene therapy may be the simplest approach, they carry substantial encumbrances. For example, approval of gene therapy treatments is unavoidably based on data derived from trials carried out over several years at most -- considerably shorter than the expected duration of the therapy. Payers may therefore be unwilling to pay large up-front sums for treatments whose long-term benefit has not been established. Additionally, large payments for medications, such as the $84,000-a-patient cost of the hepatitis C treatment Sovaldi, have been criticized in the prevailing climate of curbing health care costs. This, despite the fact that effective gene therapy may reduce the overall financial burden to the health care system.
Wilson and Brennan further note that while a liver transplant, for example, can cost up to $300,000, physicians and hospitals that "transplant livers know they will be compensated at market rates through existing contracts -- gene developers lack that assurance." Annuity payments, they say, could help address these problems.
An example of an annuity-type disbursement could be a hypothetical payment of $150,000 per year for a certain number of years for gene-therapy-based protein replacement for patients with hemophilia B -- so long as the therapy continues to work. According to the authors, the cumulative amount should be less than the cost of a one-time payment of $4-6 million, which would be the expected rate for a gene-based therapy to be comparatively priced to existing, conventional therapies for hemophilia B. "One would presume," they write, "that gene therapy will have to represent a discount in order for insurers to approve its use."
"The annuity model that we're proposing would eliminate the misguided incentive to invest in drugs and treatments with ongoing revenue streams but which require continuing, perhaps lifetime daily administration, with all the attendant inconveniences and burdens to patients and their families, as well as direct and indirect costs to the nation's health system," says Wilson.
The authors point out that gene therapy differs substantially from the case of "orphan" drugs. Development of the latter, which target rare diseases affecting small patient populations, is supported by the Orphan Drug Act of 1983, which provides pharmaceutical manufacturers with grants, tax credits, and an extended period of market exclusivity for their medications. What's more, in virtually all of these cases, the business costs of developing the drugs are further attenuated by ongoing administration of -- and payment for -- the medication over the lifetime of the patient. "The contrast with gene therapy, especially that which produces a durable cure with one administration," the authors write, "is clear."
Excerpt from:
Penn researcher and CVS Health physician urge new payment model for gene therapy
PUBLIC RELEASE DATE:
9-Sep-2014
Contact: Evy Vierstraete info@vib.be 32-924-46611 VIB (the Flanders Institute for Biotechnology)
For the first time the Jeffrey Modell Foundation is giving a research grant to a Belgian laboratory. The team of Adrian Liston from VIB-KU Leuven will use the grant to develop a gene therapy to cure children that suffer from IPEX syndrome, a rare and fatal autoimmune disorder in which the immune system attacks the body's own tissues and organs. At the moment, the only successful therapy to treat the syndrome is a bone marrow transplantation, which is not available for all children.
"This is a real chance for a cure", said group leader Adrian Liston. "The gene responsible for this disease was identified 13 years ago, but for the first time we may have learned enough about the basic biology to solve it. We should know within a year whether the gene therapy works in mice, after which we can move to patients at top speed."
The Jeffrey Modell Foundation (JMF)
JMF is a global non-profit organization for patients who suffer from Primary Immunodeficiency (PI) and their relatives. The organization is devoted to early and precise diagnosis, meaningful treatments and, ultimately, cures. Through clinical and basic research, physician education, patient support, advocacy, public awareness and new-born screening they want to make a difference in the lives of patients with PI.
Vicki and Fred Modell established the Foundation in 1987, in memory of their son Jeffrey, who died at the age of fifteen from complications of PI. During the years, the foundation has created a network of the world's leading expert immunologists. Two years ago the Child Immune Deficiencies Department of UZ Leuven was given the first certification as a "Jeffrey Modell Foundation Diagnostic and Research Center for Primary Immunodeficiencies" in Belgium.
IPEX and primary immunodeficiency (PI)
IPEX is an acronym for immune dysregulation, polyendocrinopathy (diseases affecting multiple endocrine glands), enteropathy (disorder of the intestines), and X-linked (pattern of inheritance).
Original post:
Jeffrey Modell Foundation supports Belgian research on primary immunodeficiency
On Sunday night at 11:22pm EDT, a Chinese Long March 4B satellite lifted off from the Taiyuan Satellite Launch Center. This marks the second Chinese launch in the month of September and was, like the first launch, not publicly announced until after its completion.
The Chinese news outlet Xinhua reports that the rocket was carrying two satellites. Both satellites were placed into sun-synchronous orbit.
The first was the Yaogan-21 remote sensing satellite. According to the Xinhua and Chinese government, this satellite is intended to be used for scientific experiments, natural resource survey, estimation of crop yield and disaster relief.
The second satellite is the Tiantuo-2, a small 67kg satellite which is equipped with four video cameras and is able to track and record moving targets in real time. Its reported primary purpose is to be used with a system thats capable of tracking the location of ships at sea.
However, according to space industry analyst Bill Ostrove, the purpose of both of these satellites is widely believed by Western sources to be spy satellites aimed at providing intelligence to the Chinese military.
This is the second announced launch of the Long March 4B rocket since one experienced a third stage failure in December of 2013. That rocket was carrying the CBERS-3 satellite, which was part of a series of Earth imaging satellites as part of a joint project between China and Brazil. The next satellite in the series, CBERS-4, is tentatively scheduled for launch in December 2014.
To see what has launched and whats planned to launch this month, please see ourSeptember launch schedule.
Follow me onTwitterorFacebook. Read my Forbes bloghere.
Read more here:
Freedom Fry - Wilder Mile (Urban Contact Remix)
Song: Freedom Fry - Wilder Mile (Urban Contact Remix) ORDER HERE: https://freedomfry.bandcamp.com/track/the-wilder-mile-urban-contact-remix Follow Urban Contact: https://soundclou...
By: GalaxyMusic
Excerpt from:
Day 19 - Second $100,000 sponsorship! - What is it?
Second $100000 sponsorship - What is it?* and Day 19 winner announced! All sponsorships http://www.any.tv/sponsorship What is this? Every day for 365 days, Freedom! is sponsoring...
By: Freedom!
More here:
National Wealth Center | Create Lifestyle Freedom With Global Wealth Networks LIVE
In this edition of Create Lifestyle Freedom our panel of entrepreneurs from the Global Wealth Network discuss it #39;s partnership with the National Wealth Center and how they are the vehicle of...
By: Andrew Johnson
See more here:
National Wealth Center | Create Lifestyle Freedom With Global Wealth Networks LIVE - Video
Monster Hunter Freedom Unite Online MP #288 | Akantor [High Rank]
QUEST: LV8 Rise to the Summit SUBSCRIBE, nya!: http://bit.ly/sub_barbanium Enjoyed the video, meow? Please hit that LIKE button! Played with PPSSPP v0.9.9.1 Get it here: http://www....
By: Barbanium
More:
Monster Hunter Freedom Unite Online MP #288 | Akantor [High Rank] - Video
Freedom Planet - Lilac #39;s Path #16 - Screw Your Airlocks
Meroka takes us through Freedom Planet by Galaxy Trail Games, starting with Lilac #39;s path through the game. Official Site: http://freedomplanet.galaxytrail.com/ Freedom Planet on Steam: http://stor...
By: Button Mash
Visit link:
Freedom Planet - Lilac's Path #16 - Screw Your Airlocks - Video
Lets Play Monster hunter Freedom unite (German/HD) part 4 Meine Gunlance
willkommen bei lets play Monster Hunter freedom unite Bitte das bewerten nicht vergessen --------------------------------------------------------- jetzt auch auf facebook: https://www.facebook.com/...
By: xXveenomXx
Read the original:
Lets Play Monster hunter Freedom unite (German/HD) part 4 Meine Gunlance - Video
Metro Last Light Redux: "Freedom" Achievement/Trophy Guide
Another easy achievement this time it #39;s Metro Last Light Redux: Freedom Achievement/Trophy Guide.
By: Ren Gaming
Read more from the original source:
Metro Last Light Redux: "Freedom" Achievement/Trophy Guide - Video